MyLungCancerTeam

While biomarker testing is more commonly used in advanced lung cancer cases, recent medical guidelines actually recommend biomarker testing for various stages of non-small cell lung cancer (NSCLC). Biomarker testing can help identify specific characteristics of your cancer that could influence treatment decisions, even in Show Full Answer

While biomarker testing is more commonly used in advanced lung cancer cases, recent medical guidelines actually recommend biomarker testing for various stages of non-small cell lung cancer (NSCLC). Biomarker testing can help identify specific characteristics of your cancer that could influence treatment decisions, even in earlier stages. It might be worth discussing biomarker testing further with your oncologist, as the results could potentially reveal additional treatment options or help determine if you might be eligible for clinical trials. While SBRT is a standard treatment for early-stage lung cancer, having biomarker information could be valuable for future treatment planning. Be aware that there can be some barriers to getting biomarker testing, including tissue sample availability and testing turnaround time. These factors might influence whether your healthcare team recommends testing at your current stage.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Community Clinics Lag in Biomarker Testing for Lung Cancer Treatment, Survey Finds

#KnowYourBiomarker Campaign Raises Awareness of Biomarker Testing for NSCLC